2014-12-05
acquisition of erye pharma by fosun pharma with rmb845 million to enhance the establishment of anti-凯发k8娱乐app下载
-
our company
- founded in 1994, shanghai fosun pharmaceutical (group) co., ltd. ("fosun pharma"; stock code: 600196. sh, 02196. hk) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in china. fosun pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. as a shareholder of sinopharm co., ltd., fosun pharma expands its areas in the pharmaceutical distribution and retail business.
-
our business
- fosun pharma is patient-centered and clinical needs-oriented. the company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. fosun pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. fosun pharma also vigorously explores cutting-edge technologies, such as rna, oncolytic viruses, gene therapy and protac, to enhance its innovation capabilities.
-
r&d
- through in-house research and development, co-development, in-licensing, incubation, and other diverse and multi-level cooperation models, fosun pharma, patient-centered and oriented by clinical needs, has enriched its innovative product lines. it builds technological platforms for small molecule innovator drugs, antibody drugs, and cell therapy in major areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. it also vigorously explores cutting-edge technologies, such as rna, oncolytic viruses, gene therapy and protac, to enhance its innovation.
-
sustainability
- fosun pharma has incorporated the sustainable development strategy into its overall development, and established a sound sustainable development management system. it has set up a corporate social responsibility management committee and an environmental, social and governance (esg) committee under the board of directors to promote the sustainable development of the group. moreover, a sound communication mechanism between stakeholders has been established to continuously improve their satisfaction, maintain its competitiveness in sustainable development, and lead the development of the industry.
-
investor relations
- founded in 1994, shanghai fosun pharmaceutical (group) co., ltd. ("fosun pharma"; stock code: 600196.sh, 02196.hk) is a global innovation-driven group in the pharmaceutical and healthcare industry based in china. fosun pharma strategically operates businesses in the pharmaceutical and healthcare industry, including pharmaceutical manufacturing, medical devices and medical diagnosis, and healthcare services. through equity participation in sinopharm co., ltd., fosun pharma's business extends to pharmaceutical distribution and retail.
-
news
- founded in 1994, shanghai fosun pharmaceutical (group) co., ltd. ("fosun pharma"; stock code: 600196. sh, 02196. hk) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in china. fosun pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. as a shareholder of sinopharm co., ltd., fosun pharma expands its areas in the pharmaceutical distribution and retail business.
-
careers
- we are looking for people that recognize and practice our cultural values, and can learn fast to create continuous value; possess profound professional knowledge of the industry, a wide vision of different regions, and global-level expertise in a certain field. we will also be committed to cultivating international top talent with outstanding performance and great potential.